BofA analyst Tazeen Ahmad raised the firm’s price target on Neurocrine (NBIX) to $195 from $191 and keeps a Buy rating on the shares as part of the firm’s Q4 small-to-mid cap biotech earnings preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- 3 Best Stocks to Buy Today, 1/28/2026, According to Top Analysts
- Neurocrine initiates Phase 2 study of NBI-1065890 in adults with TD
- Neurocrine price target lowered to $178 from $188 at UBS
- Neurocrine’s Ingrezza capsules show efficacy in involuntary movement disorders
- Neurocrine price target lowered to $177 from $179 at JPMorgan